Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 34

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Chronic lymphocytic leukaemia recurrent

Recruiting

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Recruiting

Study on Elranatamab for Patients with Multiple Myeloma Continuing from Previous Clinical Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Hodgkin's disease

Recruiting

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Tislelizumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute lymphocytic leukaemia recurrent+5

Recruiting

Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mb-Cart20.1
  • Sponsor:Miltenyi Biomedicine GmbH

Thalassaemia beta+1

Recruiting

Study on Luspatercept for Improving Brain Oxygenation in Patients with Non-Transfusion Dependent Thalassemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Amsterdam UMC Stichting

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Kite Pharma Inc.

Chronic lymphocytic leukaemia refractory

Recruiting

Study on PTG-CARCIK-CD19 for Adults and Children with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ptg-Carcik-Cd19
  • Sponsor:Fondazione Tettamanti

Mantle cell lymphoma stage II+2

Recruiting

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Klinikum Der Universitat Munchen AöR

Sickle cell anaemia with crisis

Recruiting

Study of Intranasal Sufentanil and Intravenous Morphine for Severe Sickle Cell Pain Crisis in Children

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Red blood cell abnormality

Recruiting

Study on the Safety of Mitapivat for Adults with Red Blood Cell Membrane Disorders

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Eurobloodnet Association

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.